Published in BMJ on April 18, 1998
Leishmaniasis: new approaches to disease control. BMJ (2003) 2.30
Use of antimony in the treatment of leishmaniasis: current status and future directions. Mol Biol Int (2011) 1.71
Visceral leishmaniasis in Malta--an 18 year paediatric, population based study. Arch Dis Child (2000) 1.58
Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial. PLoS Negl Trop Dis (2010) 1.54
Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ (2001) 1.50
Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial. PLoS Negl Trop Dis (2012) 1.41
Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother (2001) 1.39
Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Dis (2010) 1.35
Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum. Nucleic Acids Res (2009) 1.27
Leishmaniasis. Postgrad Med J (2006) 1.23
Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study. PLoS Negl Trop Dis (2010) 1.19
Leishmaniasis. Postgrad Med J (2007) 1.13
Treatment of visceral leishmaniasis. J Glob Infect Dis (2010) 1.12
An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother (2014) 1.03
Therapeutic options for visceral leishmaniasis. Drugs (2013) 1.00
The lost hope of elimination of Kala-azar (visceral leishmaniasis) by 2010 and cyclic occurrence of its outbreak in India, blame falls on vector control practices or co-infection with human immunodeficiency virus or therapeutic modalities? Trop Parasitol (2014) 0.99
Visceral leishmaniasis: new health tools are needed. PLoS Med (2005) 0.99
Differential decline in Leishmania membrane antigen-specific immunoglobulin G (IgG), IgM, IgE, and IgG subclass antibodies in Indian kala-azar patients after chemotherapy. Infect Immun (1999) 0.99
Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquine. Antimicrob Agents Chemother (2011) 0.97
Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India. J Trop Med (2011) 0.96
Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar). Ther Clin Risk Manag (2012) 0.92
Drug resistance in leishmaniasis: Newer developments. Trop Parasitol (2014) 0.88
Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide. PLoS Negl Trop Dis (2014) 0.88
Drug resistance analysis by next generation sequencing in Leishmania. Int J Parasitol Drugs Drug Resist (2014) 0.87
Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infect Dis Poverty (2016) 0.84
Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: Promising Treatments for this Neglected Disease. Front Immunol (2014) 0.83
Drug resistance in natural isolates of Leishmania donovani s.l. promastigotes is dependent of Pgp170 expression. PLoS One (2013) 0.83
Recent developments and future prospects in the treatment of visceral leishmaniasis. Ther Adv Infect Dis (2016) 0.78
Visceral Leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. Am J Trop Med Hyg (2010) 0.78
Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother (2000) 0.76
Antimony resistance during Visceral Leishmaniasis: A possible consequence of serial mutations in ABC transporters of Leishmania species. Bioinformation (2011) 0.76
Clarification of comments on trial of aminosidine in visceral leishmaniasis. BMJ (1998) 0.75
Geographical Distribution of MDR1 Expression in Leishmania Isolates, from Greece and Cyprus, Measured by the Rhodamine-123 Efflux Potential of the Isolates, Using Flow Cytometry. Am J Trop Med Hyg (2016) 0.75
Plasticity of the Leishmania genome leading to gene copy number variations and drug resistance. F1000Res (2016) 0.75
Pharmacotherapeutic options for visceral leishmaniasis-current scenario. Clin Med Pathol (2009) 0.75
A cluster of four cases of cutaneous leishmaniasis by Leishmania donovani in Cyprus: a case series. J Med Case Rep (2014) 0.75
Leishmaniasis: a review. F1000Res (2017) 0.75
Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev (1997) 4.09
Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet (1994) 2.70
Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg (1992) 2.09
Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med (1997) 1.80
Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today (1993) 1.64
Kala-azar mortality in hospitalized cases in north Bihar, India. J Assoc Physicians India (1989) 1.59
Combination therapy in Kala-azar. J Assoc Physicians India (1995) 1.54
Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg (1990) 1.51
The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother (1995) 1.37
Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med (1990) 1.34
Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis (1993) 1.29
Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial. Trans R Soc Trop Med Hyg (1995) 1.26
Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg (1993) 1.17
Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar, India. Am J Trop Med Hyg (1995) 1.08
Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom. Trans R Soc Trop Med Hyg (1993) 1.02
The effect of antibiotics of the neomycin group on experimental cutaneous leishmaniasis. Ann Trop Med Parasitol (1968) 0.97
Acute renal failure in visceral leishmaniasis treated with sodium stibogluconate. Trans R Soc Trop Med Hyg (1993) 0.93
Recurrent episodes of thrombocytopenia during treatment with sodium stibogluconate. J Antimicrob Chemother (1993) 0.93
[A study of experimental cutaneous leishmaniasis in white mice]. Med Parazitol (Mosk) (1962) 0.85
Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis. Clin Infect Dis (1993) 0.84
Pancreatitis and palindromic arthropathy with effusions associated with sodium stibogluconate treatment in a renal transplant recipient. J Infect (1990) 0.83
Averting a malaria disaster. Lancet (1999) 9.40
Artesunate combinations for treatment of malaria: meta-analysis. Lancet (2004) 7.54
Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med (2002) 6.94
Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med (1999) 5.02
Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet (2002) 4.47
Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet (2008) 4.35
Drugs for neglected diseases: a failure of the market and a public health failure? Trop Med Int Health (2001) 2.30
Economic evaluation of a policy change from single-agent treatment for suspected malaria to artesunate-amodiaquine for microscopically confirmed uncomplicated falciparum malaria in the Oussouye District of south-western Senegal. Trop Med Int Health (2005) 2.18
Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. Am Rev Respir Dis (1993) 2.07
Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int (2000) 1.93
Lymphatic leishmaniasis associated with visceral leishmaniasis. J Assoc Physicians India (1991) 1.92
Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. Lancet (2000) 1.90
Leishmaniasis chemotherapy--challenges and opportunities. Clin Microbiol Infect (2011) 1.87
Pharmacokinetics of artemisinin-type compounds. Clin Pharmacokinet (2000) 1.78
A new measure of sexual function in women with pelvic floor disorders (PFD): the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR). Int Urogynecol J (2013) 1.77
N'-[Bis(benzyl-sulfan-yl)methyl-idene]-4-meth-oxy-benzohydrazide. Acta Crystallogr Sect E Struct Rep Online (2010) 1.73
Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group. Tuber Lung Dis (1994) 1.72
Kala-azar hits again. J Trop Med Hyg (1981) 1.68
Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg (1984) 1.62
Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ (1998) 1.60
Kala-azar mortality in hospitalized cases in north Bihar, India. J Assoc Physicians India (1989) 1.59
Dexamethasone in adults with bacterial meningitis. J Assoc Physicians India (1996) 1.59
Combination therapy in Kala-azar. J Assoc Physicians India (1995) 1.54
Amodiaquine remains effective for treating uncomplicated malaria in west and central Africa. Trans R Soc Trop Med Hyg (2000) 1.51
Socio-economics of visceral leishmaniasis in Bihar (India). Trans R Soc Trop Med Hyg (2000) 1.51
The haemodynamic response to propranolol in cirrhosis with arterial hypertension: a comparative analysis with normotensive cirrhotic patients. Aliment Pharmacol Ther (2010) 1.50
A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.48
Pigeonpea genomics initiative (PGI): an international effort to improve crop productivity of pigeonpea (Cajanus cajan L.). Mol Breed (2009) 1.46
Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis (2003) 1.46
Osmotin gene expression is posttranscriptionally regulated. Plant Physiol (1992) 1.46
Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis (2003) 1.45
Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs. PLoS Negl Trop Dis (2011) 1.42
Analysis of structure and transcriptional activation of an osmotin gene. Plant Mol Biol (1992) 1.40
Artemisinin derivatives for treating uncomplicated malaria. Cochrane Database Syst Rev (2000) 1.40
The sensitivity of Leishmania species to aminosidine. J Antimicrob Chemother (1995) 1.37
Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Med Trop (Mars) (1998) 1.35
Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. J Assoc Physicians India (1991) 1.32
Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg (2002) 1.31
Artemisinin and derivatives in the treatment of uncomplicated malaria. Med Trop (Mars) (1998) 1.31
Oral miltefosine for the treatment of Indian visceral leishmaniasis. Trans R Soc Trop Med Hyg (2006) 1.30
Comparison of regimens of treatment with sodium stibogluconate in kala-azar. Br Med J (Clin Res Ed) (1984) 1.27
Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial. Trans R Soc Trop Med Hyg (1995) 1.26
The cumulative effect of allelic variation in LMW and HMW glutenin subunits on dough properties in the progeny of two bread wheats. Theor Appl Genet (1989) 1.26
Stable NaCl Tolerance of Tobacco Cells Is Associated with Enhanced Accumulation of Osmotin. Plant Physiol (1989) 1.25
A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg (2000) 1.24
Standardization of the physicochemical parameters to assess in vitro the beta-hematin inhibitory activity of antimalarial drugs. Exp Parasitol (2000) 1.24
Cold weather and myocardial infarction. Int J Cardiol (1987) 1.20
NaCl Regulation of Tonoplast ATPase 70-Kilodalton Subunit mRNA in Tobacco Cells. Plant Physiol (1991) 1.20
Plasmodium falciparum in vitro susceptibility to antimalarial drugs in Casamance (southwestern Senegal) during the first 5 years of routine use of artesunate-amodiaquine. Antimicrob Agents Chemother (2006) 1.18
Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg (1993) 1.17
Expression of Osmotin-Like Genes in the Halophyte Atriplex nummularia L. Plant Physiol (1992) 1.17
Genetic differentiation of charcoal rot pathogen, Macrophomina phaseolina, into specific groups using URP-PCR. Can J Microbiol (2005) 1.17
Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg (1996) 1.17
High-resolution mapping, cloning and molecular characterization of the Pi-k ( h ) gene of rice, which confers resistance to Magnaporthe grisea. Mol Genet Genomics (2005) 1.16
Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study. Trans R Soc Trop Med Hyg (2000) 1.15
5' sequences of rubella virus RNA stimulate translation of chimeric RNAs and specifically interact with two host-encoded proteins. J Virol (1993) 1.15
Artemisinin derivatives for treating severe malaria. Cochrane Database Syst Rev (2000) 1.14
Prevalence and determinants of hypertension in the Indian social class and heart survey. J Hum Hypertens (1997) 1.14
Dosing accuracy of artesunate and amodiaquine as treatment for falciparum malaria in Casamance, Senegal. Trop Med Int Health (2008) 1.13
Development and evaluation of near-isogenic lines for major blast resistance gene(s) in Basmati rice. Theor Appl Genet (2015) 1.12
Negative autoregulation by Ultrabithorax controls the level and pattern of its expression. Development (1993) 1.11
Colobronchial fistula: a rare cause of chronic cough. Natl Med J India (2012) 1.08
Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar, India. Am J Trop Med Hyg (1995) 1.08
ECG changes in prolonged treatment of kala-azar with antimony compounds. J Assoc Physicians India (1988) 1.07
A novel blast resistance gene, Pi54rh cloned from wild species of rice, Oryza rhizomatis confers broad spectrum resistance to Magnaporthe oryzae. Funct Integr Genomics (2012) 1.07
Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull World Health Organ (2003) 1.06
The rubella virus RNA binding activity of human calreticulin is localized to the N-terminal domain. J Virol (1995) 1.06
Identification and characterization of host factor interactions with cis-acting elements of rubella virus RNA. Arch Virol Suppl (1994) 1.06
Full moon and crime. Br Med J (Clin Res Ed) (1985) 1.05
Assessment of autonomic dysfunction in Guillain-Barré syndrome and its prognostic implications. Acta Neurol Scand (1987) 1.05
Dose-ranging studies on liposomal amphotericin B (L-AMP-LRC-1) in the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg (1999) 1.05
Consensus recommendation on the treatment of malaria in Southeast Asia. Southeast Asian J Trop Med Public Health (1998) 1.03
A randomized safety and tolerability trial of artesunate plus sulfadoxine--pyrimethamine versus sulfadoxine-pyrimethamine alone for the treatment of uncomplicated malaria in Gambian children. Trans R Soc Trop Med Hyg (2000) 1.03
A microtitre-based method for measuring the haem polymerization inhibitory activity (HPIA) of antimalarial drugs. J Antimicrob Chemother (1998) 1.02
Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom. Trans R Soc Trop Med Hyg (1993) 1.02
Changing species distribution and antimicrobial susceptibility pattern of Shigella over a 29-year period (1980-2008). Epidemiol Infect (2010) 1.02
Leishmaniasis research - the challenges ahead. Indian J Med Res (2006) 1.01
A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg (1995) 1.01
The heme moiety of malaria pigment (beta-hematin) mediates the inhibition of nitric oxide and tumor necrosis factor-alpha production by lipopolysaccharide-stimulated macrophages. Exp Parasitol (1995) 1.00
Lack of promoter IV-driven BDNF transcription results in depression-like behavior. Genes Brain Behav (2010) 1.00
Urinary MCP-1 as diagnostic and prognostic marker in patients with lupus nephritis flare. Lupus (2012) 0.99
Progress in development of vaccine against Hyalomma anatolicum anatolicum-Indian scenario. Vaccine (2008) 0.99
Macrophage preconditioning with synthetic malaria pigment reduces cytokine production via heme iron-dependent oxidative stress. Lab Invest (2000) 0.98
The ParaSight-F rapid dipstick antigen capture assay for monitoring parasite clearance after drug treatment of Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg (1997) 0.98
Influence of milk, yoghurt and calcium on cholesterol-induced atherosclerosis in rabbits. Atherosclerosis (1981) 0.98
Anaemia and periodontal disease--a correlative study. J Indian Dent Assoc (1971) 0.98
Morphine for post-caesarean section analgesia: intrathecal, epidural or intravenous? Singapore Med J (2005) 0.96
Tip60 degradation by adenovirus relieves transcriptional repression of viral transcriptional activator EIA. Oncogene (2012) 0.96
Basic helix-loop-helix transcription factors and enteroendocrine cell differentiation. Diabetes Obes Metab (2011) 0.96
DREB1/CBF transcription factors: their structure, function and role in abiotic stress tolerance in plants. J Genet (2012) 0.96
MRI features of toxoplasma encephalitis in the immunocompetent host: a report of two cases. Neuroradiology (2002) 0.95
The role of stem cells in osteoarthritis: An experimental study in rabbits. Bone Joint Res (2014) 0.95
Inhibition of retinoic acid receptor function and retinoic acid-regulated gene expression in mouse melanoma cells by calreticulin. A potential pathway for cyclic AMP regulation of retinoid action. J Biol Chem (1996) 0.94
Newer strategies for the kala-azar elimination programme in India. Indian J Med Res (2009) 0.94
Biosynthetic pathways of glycerol accumulation under salt stress in Aspergillus nidulans. Exp Mycol (1995) 0.93
Production of withaferin A in shoot cultures of Withania somnifera. Planta Med (2001) 0.93
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration. Natl Med J India (1995) 0.92